Contribute Try STAT+ Today

WASHINGTON — Food and Drug Administration Commissioner Scott Gottlieb on Wednesday accused drug makers who manufacture pricey biologic medicines of using “unacceptable” anti-competitive tactics to keep competitors off the market, costing Americans billions.

The tactics — some of which Gottlieb will refer to as a “toxin” — have prevented other drug makers from launching biosimilar medicines, highly similar versions of the same drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • While this statistic seems compelling – “Americans could have saved $4.5 billion in 2017 if all of the FDA-approved biosimilars were actually available in the United States, ” – something is missing. That savings is computed against what figure and what percentage does that saving represent? If total spend is currently is $450 Billion (2016 figure – CNBC), then 40 pct of that is $180 Billion USD. I will never see $4.5 billion USD personally, so I will agree that’s a lot but it represents a discount of ‘only’ 2.5% – scarcely impressive. Driving that spending level down to $175.5 billion USD doesn’t seem like much – “just sayin’ “

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy